DCLRE1B and cancer: Considering the hypersensitivities of hSNM1B/Apollo-depleted cells towards ICL-inducing agents such as MMC or cisplatin, drugs that are routinely used in cancer therapy, it has been hypothesized that specific hSNM1B/Apollo inhibitors could be used to sensitize tumors to these substances [20].